NRXP NRX PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2023 - Agreement with Alvogen for NRX-101 NRx Pharmaceuticals, Inc. entered into an Exclusive, Global - Development, Supply, Marketing & License Agreement with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. for the development and commercialization of NRx's candidate therapeutic product, NRX-101, for the treatment of bipolar depression with suicidality.Get access to all SEC 8-K filings of the NRX PHARMACEUTICALS INC